Luxshare Shares Rise as First-Half Profit Jumps 18% 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Tesla Raises Cybertruck Prices by $5,000 in US 
Nvidia Options Price in $280 Billion Earnings Swing 
Ampol Profit Surges as Refining Margins Hit Record Highs 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Add as a preferred source on Google
ALPHARETTA, Ga., May 02, 2018 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today announced today that its first quarter 2018 financial results will be released at approximately 7:00 a.m. on Wednesday, May 9, 2018. Following the release, Clearside will host a live conference call and webcast at 8:30 a.m. ET to discuss its financial results and provide a general business and strategic review.
The live webcast and a replay may be accessed by visiting the “Investor Relations” section at www.clearsidebio.com. Alternately, please call (844) 263-8310 (U.S.) or (213) 358-0959 (international) to participate in the live conference call. The conference ID number for the live call is 5796507. Please dial in approximately 10 minutes prior to the call. An archive of the webcast will be available until June 10, 2018.
About Clearside
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and preclinical product candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This has the potential to offer meaningful treatment benefit to patients suffering from sight-threatening diseases like uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.
Contacts:
Stephen Kilmer
Investor Relations
(678) 270-3631
[email protected]
Charles Deignan
Chief Financial Officer
(678) 270-4005
[email protected]
